Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company, announced that the shareholders of Denali Capital Acquisition Corp. approved their proposed business combination.
The approval was granted at Denali's Extraordinary General Meeting held on September 3, 2025, along with all other proposals presented. This marks a significant milestone in the spin-off process.
The combined company will operate as Semnur Pharmaceuticals, Inc. upon consummation of the Business Combination, which is expected to close in September 2025, subject to satisfaction of customary closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.